Randomized Double-Blind Comparison of Apixaban with Enoxaparin for Thromboprophylaxis after Knee Replacement: The ADVANCE-1 Trial

医学 阿哌沙班 静脉造影 肺栓塞 外科 安慰剂 随机对照试验 深静脉 拜瑞妥 血栓形成 华法林 内科学 心房颤动 病理 替代医学
作者
Michael R. Lassen,Alexander Gallus,Graham F. Pineo,Gary E. Raskob
出处
期刊:Blood [Elsevier BV]
卷期号:112 (11): 31-31 被引量:14
标识
DOI:10.1182/blood.v112.11.31.31
摘要

Abstract Thromboprophylaxis with enoxaparin after total knee replacement is an evidence-based recommended standard of care. The ADVANCE-1 clinical trial was a phase III randomized double-blind multicenter study that evaluated the efficacy and safety of apixaban, an oral direct factor Xa inhibitor, 2.5 mg orally bid compared with enoxaparin 30 mg subcutaneously every 12 hours for preventing venous thromboembolism after total knee replacement. Apixaban (or oral placebo) and enoxaparin (or subcutaneous placebo) were begun 12 to 24 hours post-operatively (mean 20 hours) and continued until mandatory bilateral venography was completed at 12± 2 days. The primary efficacy outcome was the composite of deep-vein thrombosis (DVT) by venography; symptomatic, objectively confirmed DVT or pulmonary embolism (PE); or death from any cause during the treatment period. The secondary efficacy outcome was the composite of objectively confirmed proximal DVT or PE, or death. The primary safety outcome was bleeding, including major bleeding (defined by ISTH criteria), clinically relevant non-major bleeding, and minor bleeding. All outcome events were interpreted by a central independent adjudication committee without knowledge of treatment. The study hypothesis was that apixaban would be as effective as enoxaparin based on a pre-specified non-inferiority margin in which the upper limit of the two-sided 95% CI is < 1.25 for relative risk and < 5.6% for the absolute risk difference for the primary efficacy outcome. A total of 3195 patients from 129 sites in 14 countries were randomized. The primary efficacy outcome occurred in 104 of 1157 patients (8.99%) given apixaban and in 100 of 1130 (8.85%) given enoxaparin (relative risk 1.02, 95% CI 0.78 to 1.32, one-sided p= 0.064 for non-inferiority, statistical criteria not met). The secondary efficacy outcome occurred in 26 patients (2.05%) given apixaban and in 20 patients (1.64%) given enoxaparin. Symptomatic PE occurred in 16 patients (1.0%) who received apixaban (2 fatal) and in 7 patients (0.44%) given enoxaparin (0 fatal); the majority of the PE in apixaban patients occurred within 48 hours postoperatively. Major or clinically relevant non-major bleeding occurred in 46 of 1596 patients (2.88%) given apixaban, compared with 68 patients (4.28%) given enoxaparin (absolute difference 1.46%, two-sided p=0.034). Major bleeding occurred in 11patients (0.69%) who received apixaban and in 22 patients (1.39%) who received enoxaparin (two-sided p=0.053). Elevated levels of liver transaminase enzymes were uncommon (2% to 3%) in both groups; no patient given apixaban met Hy’s criteria. Myocardial infarction or stroke occurred in only one patient who received apixaban (0.06%) and in 5 patients (0.31%) given enoxaparin. The lower-than-expected incidence of the primary efficacy outcome in the enoxaparin group resulted in an undersized study to meet the pre-defined statistical criteria for non-inferiority in spite of a similar incidence with the apixaban regimen. This is the first phase III trial to demonstrate a potential advantage of the new oral anticoagulants for bleeding. The apixaban regimen resulted in less clinically relevant bleeding than enoxaparin 30 mg given every 12 hours. Maintaining this advantage while optimizing efficacy with an altered dosing regimen, either by earlier postoperative dosing or by a slightly increased dose, would be an important advance in patient care.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
忧心的寄松完成签到,获得积分10
1秒前
在水一方应助3080采纳,获得10
3秒前
3秒前
4秒前
kwen完成签到 ,获得积分10
5秒前
大个应助毛益聪采纳,获得10
5秒前
5秒前
6秒前
上官若男应助不爱吃饭采纳,获得30
7秒前
半截神经病完成签到,获得积分20
8秒前
花花发布了新的文献求助10
10秒前
11秒前
12秒前
14秒前
还好完成签到,获得积分10
15秒前
15秒前
17秒前
淡淡的苑睐完成签到,获得积分10
17秒前
科目三应助幸福的半蕾采纳,获得30
18秒前
毛益聪发布了新的文献求助10
19秒前
晒太阳的乌龟完成签到,获得积分10
19秒前
踏实的南琴完成签到 ,获得积分10
20秒前
24秒前
丘比特应助包谷林采纳,获得10
25秒前
25秒前
27秒前
28秒前
29秒前
CR7应助窦长昕采纳,获得20
30秒前
Akim应助guangshuang采纳,获得10
31秒前
却却发布了新的文献求助20
32秒前
32秒前
洁净的静芙完成签到,获得积分10
33秒前
34秒前
34秒前
Chanpi完成签到,获得积分10
35秒前
量子星尘发布了新的文献求助10
35秒前
36秒前
36秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3959179
求助须知:如何正确求助?哪些是违规求助? 3505472
关于积分的说明 11124101
捐赠科研通 3237190
什么是DOI,文献DOI怎么找? 1789003
邀请新用户注册赠送积分活动 871507
科研通“疑难数据库(出版商)”最低求助积分说明 802824